Evidence map›Paper›PMID 38003724›Full record

ArticleInternational journal of molecular sciences2023

The Protective Effects of

Hai-Jun Fu, Xing-Yue Zhou, Ya-Ping Li, Xue Chen, Yan-Ni He, Da-Lian Qin, Lu Yu, Chong-Lin Yu, Jian-Ming Wu, An-Guo Wu and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Gaultheria leucocarpa inhibits Aβ fibrillization and enhances mitophagy-mediated degradation of pathogenic proteins.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  4. Review
  5. 4,4'-methylenediphenol reduces Aβ-induced toxicity in aFrontiers in aging neuroscience · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Hai-Jun FuSichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.
Xing-Yue ZhouSichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.
Ya-Ping LiSichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.
Xue ChenSichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.
Yan-Ni HeSichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.
Da-Lian QinSichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.
Lu YuSichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.
Chong-Lin YuSichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.
Jian-Ming WuSichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.ORCID 0000-0002-6136-7469
An-Guo WuSichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.ORCID 0000-0002-9850-7576
Xiao-Gang ZhouSichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.ORCID 0000-0002-2574-3973
Southwest Medical University · CN

Funding

the National Natural Science Foundation of China 81801398The Science and Technology Planning Project of Sichuan Province, China 2021YJ0180The Science and Technology Planning Project of Sichuan Province, China 2022YFS0620
6 · The paper itself

Abstract

Alzheimer's disease (AD) presents a significant challenge to global healthcare systems, with current treatments offering only modest relief and often bringing unwanted side effects, necessitating the exploration of more effective and safer drugs. In this study, we employed the

Indexed as

Alzheimer DiseaseCaenorhabditis elegans ProteinsAmyloid beta-PeptidesAnimalsAnimals, Genetically ModifiedCaenorhabditis elegansDisease Models, AnimalEtherEthersEthyl EthersHumansAmyloid beta-PeptidesCaenorhabditis elegans ProteinsEtherEthersEthyl EthersAlzheimer’s diseaseautophagyAβReineckia carnea ether fractionTau

Identifiers

PMID38003724
PMCPMC10672099
OpenAlexW4388835004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.